ABSTRACT
Using cobra venom factor to inhibit the complement cascade via C3 molecule exhaustion in (FBS) and 200 μg/ml of G418 to select for retention of the gp33 minigene.
79
Enzyme-linked immunosorbent assay.
80
C3 molecule concentration was tested in mice sera at the indicated time points by ELISA.
81
Briefly, blood was harvested and incubated at 37°C to coagulate. Samples were centrifuged and 82 the serum fraction was used. Serial dilutions were added onto an IgM-coated 96-well plate dihydrochloride (Sigma-Aldrich, Oakville, ON) was then used for the detection of C3 molecules.
87
Optical density was measured by spectrophotometry at 490 nm.
88
In vivo studies. intraperitoneally two days prior to decomplementation (Fig. S2) .
96
Flow cytometry.
97
Spleen and tumors were recovered from mice and dissociated in vitro to achieve single-98 cell suspensions using nylon 100 μm cell strainers (BD Falcon). Cells were washed, resuspended 99 in phosphate-buffered saline containing 1% bovine serum albumin and 0.1% sodium azide 100 (FACS buffer), and incubated with directly conjugated primary antibodies for 30 minutes at 4°C. 
146
Some complement activation products, like the anaphylatoxins C3a and C5a, are potent 147 proinflammatory mediators and it is now well recognized that inflammation is able to both 148 promote and exacerbate tumor growth.
149
To establish the role of the complement system in the generation of an anti-tumoral 150 immune response, transient decomplementation was performed using cobra venom factor (CVF) 151 6 days following tumor administration, at the time when T cell priming is expected to occur.
152
CVF is a structural and functional analog of the C3 molecule, which will act as a C3/C5 153 convertase. CVF-containing convertases are more stable and resistant to regulatory inhibitors and (Fig. 1A) . Even if this was not associated with a significant increase in the percentage of 161 tumor-infiltrating immune cells 9 days following decomplementation (Fig. 1B) , it modulated the (Fig. 3A) . We then sought to determine if the antibody is complement-mediated, thus required prior to CVF treatment. We found that in the 218 absence of NK cells, CVF treatment had no effect on tumor implantation and early development 219 demonstrating that NK cells were necessary for the decreased tumor growth observed following 220 decomplementation (Fig. 4A ).
221
Considering that T cell activation in the spleen is also increased in the absence of (Fig. 4B) . Accordingly, the enhancement of gp33-specific CTL induction by CVF was 227 also abolished in the absence NK cells indicating that the effect of decomplementation on early 228 tumor growth is largely mediated by CTLs (Fig. 4B) . However, CVF-mediated 229 decomplementation did not lead to superior levels of gp33-specific cytotoxicity as assessed by
230
CD107a expression, a marker of recent degranulation (Fig. 4C) could then suppress lymphocyte function (Fig. 4D) . 
